What is Fitorine (GW-0742)?
GW0742 is a small-molecule PPARδ research agonist. The catalog's Fitorine name is a commercial label, not an independently established clinical identity or efficacy claim.
Mechanism & research focus
It activates the nuclear receptor PPARδ in experimental transcription assays. Selectivity is concentration-dependent: later research found additional nuclear-receptor interactions at higher experimental concentrations.
What the research covers
The 2003 discovery paper described GW0742 and the separate compound GW501516 within a medicinal-chemistry series. A 2013 study characterized wider receptor effects, including interference with vitamin-D-receptor and androgen-receptor systems under certain assay conditions.
What remains uncertain
GW0742 is not GW501516; clinical or toxicological findings cannot be transferred solely because both target PPARδ. The cited studies do not establish improved endurance or metabolic health in humans, nor validate a capsule formulation. Receptor potency alone is not clinical evidence.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Novel selective small-molecule PPARδ agonists: synthesis and biological activity ↗
Original characterization distinguishes GW0742 from GW501516.
GW0742 interacts weakly with multiple nuclear receptors ↗
Shows concentration-dependent activity beyond the principal PPARδ research target.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: Fitorine (GW-0742) research guide ↗